Geron/$GERN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Geron
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Ticker
$GERN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
229
ISIN
US3741631036
Website
Geron Metrics
BasicAdvanced
$879M
-
-$0.21
0.76
-
Price and volume
Market cap
$879M
Beta
0.76
52-week high
$5.06
52-week low
$1.17
Average daily volume
10M
Financial strength
Current ratio
7.865
Quick ratio
6.326
Long term debt to equity
45.034
Total debt to equity
45.399
Interest coverage (TTM)
-5.77%
Profitability
EBITDA (TTM)
-133.736
Gross margin (TTM)
31.88%
Net profit margin (TTM)
-119.54%
Operating margin (TTM)
-115.49%
Revenue per employee (TTM)
$510,000
Management effectiveness
Return on assets (TTM)
-16.07%
Return on equity (TTM)
-45.35%
Valuation
Price to revenue (TTM)
7.851
Price to book
3.28
Price to tangible book (TTM)
3.28
Price to free cash flow (TTM)
-4.467
Free cash flow yield (TTM)
-22.39%
Free cash flow per share (TTM)
-30.89%
Growth
Revenue change (TTM)
22,264.04%
Earnings per share change (TTM)
-38.93%
3-year revenue growth (CAGR)
338.53%
10-year revenue growth (CAGR)
57.78%
3-year earnings per share growth (CAGR)
-16.36%
10-year earnings per share growth (CAGR)
-1.02%
What the Analysts think about Geron
Analyst ratings (Buy, Hold, Sell) for Geron stock.
Bulls say / Bears say
Geron's flagship product, Rytelo, has shown promising initial market performance, indicating potential for significant revenue growth. (Investing.com)
Analysts have set an average target price of $3.69 for Geron's stock, suggesting a potential upside of approximately 136.38%. (Director's Talk Interviews)
Institutional investors, such as J. Goldman & Co LP, have significantly increased their holdings in Geron, reflecting confidence in the company's future prospects. (MarketBeat)
Geron's financial performance remains a concern, with a net loss of $174.57 million in 2024, highlighting ongoing profitability challenges. (Investing.com)
The company faces legal challenges, including class-action lawsuits alleging misleading statements about Rytelo's growth prospects, which could impact investor confidence. (DCFmodeling.com)
Analyst downgrades, such as HC Wainwright & Co.'s shift from 'Buy' to 'Neutral,' may negatively influence market sentiment. (MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Geron Financial Performance
Revenues and expenses
Geron Earnings Performance
Company profitability
Geron News
AllArticlesVideos
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·3 weeks ago
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 months ago
GERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Geron stock?
Geron (GERN) has a market cap of $879M as of July 11, 2025.
What is the P/E ratio for Geron stock?
The price to earnings (P/E) ratio for Geron (GERN) stock is 0 as of July 11, 2025.
Does Geron stock pay dividends?
No, Geron (GERN) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Geron dividend payment date?
Geron (GERN) stock does not pay dividends to its shareholders.
What is the beta indicator for Geron?
Geron (GERN) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.